Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

E-Lert: Updates on Therapeutic Options for Breast Cancer - Targeted Agents

Release Date: December 3, 2009| Expiration Date: December 3, 2010
0.5 AMA PRA Category 1 Credit(s)™| Dec 3, 2009, E-Lert

Upon completion of this educational activity, you should be able to:

  • Assess recent data regarding the safety and efficacy of inhibitors of PARP in patients with advanced breast cancer
  • Evaluate recent data concerning the efficacy of antiangiogenic therapy combined with various cytotoxic agents for the treatment of MBC
  • Discuss recent advances regarding the efficacy and safety of HER2-targeted therapy beyond progression on standard therapies for HER2+ advanced breast cancer

Choose a Participation Option

Take this activity for credit

To claim credit for this activity you must:

  • Take the Pretest
  • Participate in the Activity
  • Take the Posttest
  • Take the Evaluation
  • Claim your Credit Amount & Certificate Type
Just show me the activity

If you do not wish to claim credit:

You may bypass all CE information, tests and evaluations and go straight to the activity.

You may not request credit after viewing the activity.

Take for credit

I wish to participate in this
activity and claim credit.

View without credit

I wish to view the activity
without claiming credit.

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology